Clinical Trial Update: MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC [Phase 1]

View source ↗

Summary

Phase I study of MesomiR-1 (TargomiRs) for recurrent malignant pleural mesothelioma and non-small cell lung cancer; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• MesomiR-1 (TargomiRs)

Snippet

Sponsor: Asbestos Diseases Research Foundation | Conditions: Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer | Phase 1 | Status: COMPLETED